Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1869-6961
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale ; volume:9 ; number:5 ; day:10 ; month:8 ; year:2018 ; pages:2107-2116 ; date:10.2018
Diabetes therapy ; 9, Heft 5 (10.8.2018), 2107-2116, 10.2018

Creator
Kubota, Yoshiaki
Contributor
Yamamoto, Takeshi
Tara, Shuhei
Tokita, Yukichi
Yodogawa, Kenji
Iwasaki, Yuki
Takano, Hitoshi
Tsukada, Yayoi
Asai, Kuniya
Miyamoto, Masaaki
Miyauchi, Yasushi
Kodani, Eitaro
Sato, Naoki
Tanabe, Jun
Shimizu, Wataru
SpringerLink (Online service)

DOI
10.1007/s13300-018-0480-7
URN
urn:nbn:de:101:1-2018111113552579605431
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Kubota, Yoshiaki
  • Yamamoto, Takeshi
  • Tara, Shuhei
  • Tokita, Yukichi
  • Yodogawa, Kenji
  • Iwasaki, Yuki
  • Takano, Hitoshi
  • Tsukada, Yayoi
  • Asai, Kuniya
  • Miyamoto, Masaaki
  • Miyauchi, Yasushi
  • Kodani, Eitaro
  • Sato, Naoki
  • Tanabe, Jun
  • Shimizu, Wataru
  • SpringerLink (Online service)

Other Objects (12)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity

Periprocedural Myocardial Infarction

Periprocedural Myocardial Infarction

Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction

Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

Type II Myocardial Infarction

Type II Myocardial Infarction

Pregnancy-related myocardial infarction

Pregnancy-related myocardial infarction

An unusual myocardial infarction

An unusual myocardial infarction

Activation of oxytocin neurons in the paraventricular nucleus drives cardiac sympathetic nerve activation following myocardial infarction in rats

Activation of oxytocin neurons in the paraventricular nucleus drives cardiac sympathetic nerve activation following myocardial infarction in rats

Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction

Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction

Related objects